Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Trbusek

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Leukemia Research|August 26, 2021
Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustionMarek Borsky, Viera Hrabcakova, Jitka Novotna, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti|August 15, 2019
Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of VariantsEva Machackova, Kathleen Claes, Miroslava Mikova, et al.
Experimental Hematology|June 28, 2014
Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximabLudmila Sebejova, Marek Borsky, Zuzana Jaskova, et al.
Leukemia Research|May 5, 2019
Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experienceMichaela Spunarova, Nikola Tom, Sarka Pavlova, et al.
Leukemia & Lymphoma|January 11, 2019
ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patientsAndrea Mareckova, Jitka Malcikova, Nikola Tom, et al.
European Journal of Haematology|November 21, 2008
Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabineSona Cejkova, Ludmila Rocnova, David Potesil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemiaMartin Trbusek, Jana Smardova, Jitka Malcikova, et al.
Leukemia & Lymphoma|January 8, 2013
The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapyJitka Malcikova, Filip Razga, Tomas Jurcek, et al.
Experimental Hematology|July 10, 2012
Gene expression profiling of acute graft-vs-host disease after hematopoietic stem cell transplantationJan Verner, Jitka Kabathova, Alexandra Tomancova, et al.
Cancer Genetics and Cytogenetics|January 27, 2009
Inactivation of p53 and amplification of MYCN gene in a terminal lymphoblastic relapse in a chronic lymphocytic leukemia patientKaterina Stano-Kozubik, Jitka Malcikova, Boris Tichy, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Leukemia Research|August 26, 2021
Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustionMarek Borsky, Viera Hrabcakova, Jitka Novotna, et al.
Klinicka Onkologie : Casopis Ceske a Slovenske Onkologicke Spolecnosti|August 15, 2019
Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of VariantsEva Machackova, Kathleen Claes, Miroslava Mikova, et al.
Experimental Hematology|June 28, 2014
Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximabLudmila Sebejova, Marek Borsky, Zuzana Jaskova, et al.
Leukemia Research|May 5, 2019
Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experienceMichaela Spunarova, Nikola Tom, Sarka Pavlova, et al.
Leukemia & Lymphoma|January 11, 2019
ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patientsAndrea Mareckova, Jitka Malcikova, Nikola Tom, et al.
European Journal of Haematology|November 21, 2008
Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabineSona Cejkova, Ludmila Rocnova, David Potesil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemiaMartin Trbusek, Jana Smardova, Jitka Malcikova, et al.
Leukemia & Lymphoma|January 8, 2013
The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapyJitka Malcikova, Filip Razga, Tomas Jurcek, et al.
Experimental Hematology|July 10, 2012
Gene expression profiling of acute graft-vs-host disease after hematopoietic stem cell transplantationJan Verner, Jitka Kabathova, Alexandra Tomancova, et al.
Cancer Genetics and Cytogenetics|January 27, 2009
Inactivation of p53 and amplification of MYCN gene in a terminal lymphoblastic relapse in a chronic lymphocytic leukemia patientKaterina Stano-Kozubik, Jitka Malcikova, Boris Tichy, et al.
Pageof 4